Baseline Evaluations Before Starting Acitretin in an Older Male Patient
Before initiating acitretin in an older male patient, you must obtain comprehensive laboratory testing including liver function tests (ALT, AST, GGT, alkaline phosphatase, bilirubin), fasting lipid panel (cholesterol and triglycerides), renal function tests (urea, electrolytes, creatinine), and fasting glucose, along with a detailed clinical history focusing on liver disease, renal disease, diabetes, alcohol use, and current medications. 1
Required Laboratory Tests
The British Association of Dermatologists guidelines provide clear baseline requirements 1:
Liver Function Assessment
- Check: ALT, AST, GGT, alkaline phosphatase, and bilirubin
- Rationale: Acitretin is contraindicated with significant hepatic impairment (enzymes >2 times normal), hepatitis, or alcohol abuse 1
- Critical threshold: Do not start if transaminases are elevated to three times their upper normal limit 1
Lipid Profile (Fasting)
- Check: Total cholesterol and triglycerides
- Rationale: 66% of patients develop hypertriglyceridemia and 33% develop hypercholesterolemia during treatment 1, 2
- High-risk consideration: Older patients with diabetes, obesity, or alcoholism have increased risk and need more frequent monitoring 1
Renal Function
- Check: Urea, electrolytes, and creatinine
- Rationale: Acitretin should be avoided in moderate to severe renal impairment 1
- Important caveat: While traditionally contraindicated in end-stage renal disease, recent evidence suggests acitretin may be used cautiously in hemodialysis patients with close monitoring of alkaline phosphatase and bilirubin 3
Glucose Metabolism
- Check: Fasting glucose
- Rationale: Acitretin increases insulin sensitivity and can cause hypoglycemia, particularly in diabetic patients on antidiabetic medications 1, 2
Essential Clinical History
Medical History to Elicit 1:
Liver-related:
- Past or current liver disease
- Excess alcohol intake (critical—alcohol converts acitretin to etretinate, extending teratogenic risk) 1
- Current hepatotoxic medications
Renal-related:
- History of renal disease
- Current nephrotoxic medications
Metabolic conditions:
- Diabetes mellitus and current antidiabetic medications
- History of lipid metabolism disturbances
- Obesity
- Alcoholism
Medication review for interactions 1:
- Methotrexate (increased hepatotoxicity risk—contraindicated) 2
- Tetracyclines (risk of pseudotumor cerebri—contraindicated) 2
- Antidiabetic agents (increased hypoglycemia risk)
- Phenytoin (altered protein binding)
- Vitamin A supplements (must not exceed 2400-3000 IU daily) 1
Special Considerations for Older Male Patients
Blood Donation Restriction
Counsel the patient: He cannot donate blood during treatment and for at least 1 year (FDA label states 3 years 2) after discontinuation because women of childbearing potential must not receive blood from acitretin-treated patients 1
Bone Health Monitoring
- No routine radiography needed at baseline—it's potentially harmful due to radiation exposure 1
- Only obtain targeted X-rays if musculoskeletal symptoms develop during treatment
- Long-term use can cause periosteal thickening, osteophyte formation, and DISH-like changes 1
Cardiovascular Risk Assessment
Given that older males may have baseline cardiovascular risk factors, document:
- History of cardiovascular disease
- Current cardiovascular medications
- Important: Hypertriglyceridemia and lowered HDL may increase cardiovascular risk, and there have been postmarketing reports of myocardial infarction in patients on acitretin 2
Common Pitfalls to Avoid
Don't skip the alcohol history: This is critical because alcohol consumption converts acitretin to etretinate, which has a 120-day half-life versus acitretin's 50-60 hours 4
Don't start if baseline labs are significantly abnormal: Enzymes >2 times normal or moderate-to-severe renal impairment are contraindications 1
Don't forget to counsel about sun exposure: UV radiation effects are enhanced by retinoid therapy 1
Don't overlook vitamin A intake: Patients must not exceed recommended daily allowance (2400-3000 IU daily) to avoid hypervitaminosis A 1
Don't initiate without establishing monitoring plan: The American Academy of Dermatology guidelines recommend monitoring liver enzymes and lipids every 1-2 weeks until stable (usually 4-8 weeks), then every 6-12 weeks 5
Documentation Requirements
Before prescribing, document:
- All baseline laboratory values
- Detailed medication history with specific attention to contraindicated drugs
- Alcohol consumption patterns
- Patient counseling regarding blood donation restrictions
- Patient understanding of mucocutaneous side effects (nearly universal) 4
- Plan for follow-up monitoring
The supervising dermatologist bears responsibility for initiation and monitoring 1, though this may be shared with the patient's general practitioner following mutual agreement and locally agreed protocol.